Ana Luiza Corrêa Silva

Ana Luiza Corrêa Silva

Auto-generated profile, based on publicly available information

Ana Luiza Corrêa Silva

Universidade Federal de São João del-Rei

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
ASAna Luiza Corrêa Silva
Ana Luiza Corrêa Silva
JPJoão Pedro Vasconcelos Paolinelli
João Pedro Vasconcelos Paolinelli
PCPaula Camilo Contaiffer
Paula Camilo Contaiffer
KQKarla Amaral Nogueira Quadros
Karla Amaral Nogueira Quadros
FMFlávio Augusto de Morais
Flávio Augusto de Morais
AOAlba Otoni
Alba Otoni
Objective: to evaluate potential severe and moderate drug interactions in patients with chronic kidney disease (CKD) not on dialysis and using polypharmacy. Methodology: cross-sectional study carried out in a city in the center-west of Minas Gerais/Brazil. The population consisted of patients with non-dialysis kidney disease treated at the municipal nephrology clinic. Descriptive analysis was used to characterize the sociodemographic, clinical, and laboratory profile of the population. Bivariate logistic regression analysis was applied to determine factors associated with potential drug interactions. Variables with p-value < 0.20 were taken to the multivariate model. Results: Of the total of 75 participants, most were female, elderly and white. Among them, 60% (45/75) were in stage 3A and 3B of kidney disease. No significant association was found between the use of polypharmacy and Estimated Glomerular Filtration Rate (p <0.671). Among the 630 drug prescriptions evaluated, a total of 833 drug interactions (MI's) were found, with 7.68% (n=64) being severe, 75.27% (n=627) moderate and 17.05% (n= 142) light. Use of polypharmacy was identified in 81.3% (61/75) of patients, with an average of nine medications per patient. Conclusions: high rates of moderate drug interactions were found, in addition to the presence of severe interactions. The association of multiple drugs in pharmacotherapy, especially for elderly patients with kidney disease, is often unavoidable and, therefore, deserves special attention not only from prescribing professionals but also from the entire team in order to safeguard the safety of these patients, avoiding events adverse events related to MIs.